Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

Dimitri Semenikhin, the retail trader behind the Beyond Meat stock rally is piling into a small biotech that recently pivoted ...

Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Importantly, BGE-102 is an oral candidate. The current leaders in the anti-obesity market are administered via subcutaneous ...

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks.

Houser Labs, a startup that will offer incubator lab space, expects to be fully operational early next year in a south Fargo ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...